Trials / Unknown
UnknownNCT01248117
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab (2.0mg) Prospectively
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Retina Consultants of Hawaii · Academic / Other
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Accepted
Summary
Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed with open label 2.0mg ranibizumab.
Detailed description
Patients will be followed with spectral oct, 4m BCVA, ICG, FA and monthly eye examinations for one year.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab 2.0mg | Monthly, intravitreal injection 0.05ml |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2012-12-01
- Completion
- 2013-02-01
- First posted
- 2010-11-25
- Last updated
- 2010-11-25
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01248117. Inclusion in this directory is not an endorsement.